You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Strategies to Mitigate Risk for Invasive Mold Infections After Natural Disasters

  • Authors: Tom Chiller, MD, MPHTM; Mitsuru Toda, MS, PhD; Jose Vazquez, MD; Luis Ostrosky-Zeichner, MD
  • CME / ABIM MOC / CE Released: 3/18/2022; Reviewed and Renewed: 3/18/2023
  • Valid for credit through: 3/18/2024
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    Nurses - 0.50 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for primary care physicians, infectious disease specialists, and nurses.

The goal of this activity is to educate providers on the risk of invasive mold infections (IMIs) to immunocompromised patients in post-flood settings. As a result of this education, providers will have improved recognition of IMIs and will be in a position to improve clinical care among these patients.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Risk for mold exposure following hurricanes, flooding, and natural disasters
    • Strategies to mitigate risk for invasive mold infections
  • Have greater competence related to
    • Identification of individuals at increased risk for invasive mold infections
  • Demonstrate greater confidence in their ability to
    • Collaborate with the multidisciplinary team to mitigate exposure to invasive mold infections among immunocompromised patients


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Tom Chiller, MD, MPHTM

    Chief and Medical Epidemiologist
    Mycotic Diseases Branch
    Division of Foodborne, Waterborne, and Environmental Diseases
    Centers for Disease Control and Prevention
    Atlanta, Georgia

    Disclosures

    Disclosure: Tom Chiller, MD, MPHTM, has disclosed no relevant financial relationships.

  • Mitsuru Toda, MS, PhD

    Epidemiologist
    Mycotic Diseases Branch
    Centers for Disease Control and Prevention
    Atlanta, Georgia

    Disclosures

    Disclosure: Mitsuru Toda, MS, PhD, has disclosed no relevant financial relationships.

  • Jose Vazquez, MD

    Division Chief and Professor of Medicine
    Division of Infectious Diseases
    Augusta University
    Chief, Antimicrobial Stewardship Service
    AU Health
    Augusta, Georgia

    Disclosures

    Disclosure: Jose Vasquez, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Amplyx; Cidara; F2G; Scynexis
    Served as a speaker or a member of a speakers bureau for: Astellas

  • Luis Ostrosky-Zeichner, MD

    Professor and Chief, Division of Infectious Diseases
    Vice Chair of Medicine for Healthcare Quality
    McGovern Medical School
    Medical Director for Epidemiology and Antimicrobial Stewardship
    Memorial Hermann Texas Medical Center
    Houston, Texas

    Disclosures

    Disclosure: Luis Ostrosky-Zeichner, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: ACI Clinical; Amplyx; Cidara; F2G; Octapharma; Viracor
    Served as a speaker or a member of a speakers bureau for: Abbott; Gilead; Pfizer; Stendhal
    Received grants for clinical research from: Gilead; Scynexis

Editor

  • Karen Badal, MD, MPH

    Senior Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: Karen Badal, MD, MPH, has disclosed no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM’s) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Strategies to Mitigate Risk for Invasive Mold Infections After Natural Disasters

Authors: Tom Chiller, MD, MPHTM; Mitsuru Toda, MS, PhD; Jose Vazquez, MD; Luis Ostrosky-Zeichner, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 3/18/2022; Reviewed and Renewed: 3/18/2023

Valid for credit through: 3/18/2024

processing....

  • Print